Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary

February 13, 2025

London Stock Exchange GB Health Care Biotechnology earnings 16 min

Earnings Call Speaker Segments

Operator

operator
#1

Hello. Welcome to the conference call on Palatin Technologies, Inc.'s operating results for the second quarter of fiscal year 2025. Right now, everyone is in listen-only mode. After the formal presentation, there will be a question and answer session. Please note that this conference call is being recorded. Before we get into our remarks, I want to remind everyone that statements made by Palatin Technologies, Inc. are not historical facts and could be forward-looking statements. Such statements rest on assumptions that may or may not turn out to be accurate, and actual results could differ materially from what is anticipated because of various risks and uncertainties discussed in the company's most recent filings with the Securities and Exchange Commission. When evaluating these forward-looking statements regarding Palatin Technologies, Inc.'s prospects, please weigh such risks and uncertainties carefully. I would now like to hand the call over to our host, Dr. Carl Spana, President and Chief Executive Officer of Palatin Technologies, Inc. Please go ahead.

Carl Spana

executive
#2

Thanks, and good morning, everyone. Welcome to the conference call for Palatin Technologies, Inc.'s second quarter of fiscal year 2025. I'm Dr. Carl Spana, the CEO and President of Palatin Technologies, Inc. Joining me today is Steve Wills, who serves as Palatin Technologies, Inc.'s Chief Financial Officer and Chief Operating Officer. At this point I'll hand things over to Steve, and he will provide the financial update.

Steve Wills

executive
#3

Thanks, Carl, and hello everyone. Turning to our financial results, let's begin with revenue. Following the closing of the sale of the worldwide rights for female sexual dysfunction to CoSette Pharmaceuticals for up to $171 million in December of 2023, Palatin Technologies, Inc. recorded no product sales to pharmacy distributors for the second quarter ended December 31, 2024. In the second quarter ended December 31, 2023, gross product sales came to $4.3 million, and net product revenue was $2 million. On operating expenses, total operating expenses were $2.6 million net of a $2.5 million gain on the sale by lessee for the second quarter ended December 31, 2024, versus $0.9 million net of a $7.8 million gain on the sale by lessee for the comparable quarter in 2023. That increase mainly reflected the decrease in gain on the sale by lessee to CoSette for the second quarter ended December 31, 2024. As for other income and expense, total other income expense net consists mainly of foreign currency transaction gains and losses, and the change in fair value of warrant liabilities, which Palatin Technologies, Inc. had recorded as a liability on the consolidated financial statement. For the quarter ended December 31, 2023, Palatin Technologies, Inc.

Steve Wills

executive
#4

We booked a fair value adjustment loss of $8.1 million, along with offering expenses of $0.7 million. Turning to cash flows, Palatin Technologies, Inc.'s net cash used in operations for the quarter ended December 31, 2024, came in at $4.8 million, versus net cash used in operations of $10.5 million for the same period in 2023. That drop in net cash used in operations stems mainly from the lower gain on the sale by lessee during the period, and secondarily from working capital changes. On net loss, Palatin Technologies, Inc.'s net loss for the quarter ended December 31, 2024, was $2.4 million, compared with a net loss of $7.8 million for the same period in 2023. The smaller net loss for the 2024 quarter versus the quarter ended in 2023 was driven primarily by the change in fair values of the warrant liability and the elimination of our leasing net product revenue and selling expenses, offset by the decrease on the gain of the sale by lessee. As for our cash position, as of December 31, 2024, Palatin Technologies, Inc.'s cash and cash equivalents stood at $3.4 million, compared to $2.4 million at September 30, 2024, and $9.5 million as of June 30, 2024.

Steve Wills

executive
#5

As of December 31, 2024, we held $3.4 million in cash and cash equivalents — and that figure doesn't take into account the $4.3 million in net proceeds from an equity offering that closed in February 2025. We're actively working with several potential sources of funding to meet our future operating cash needs. At this point, I'll hand the call back to Carl.

Carl Spana

executive
#6

Thanks, Steve. Now I’ll walk through a few of the quarter’s operating highlights. To begin, our phase two signal detection study, BMP 801, which assesses the safety and efficacy of coadministering the melanocortin 4 receptor agonist brimonidine together with risapatide, a GLP-1, GIP-1 dual agonist. That work is being conducted in patients who have generalized obesity. The study is finished, and the database has been locked. Top line data from it should be ready later this month. Two primary research questions were built into the design: does coadministration produce greater weight loss, and could treatment using an amyloidone 4 receptor agonist serve weight loss maintenance by blunting the weight regain observed after incretin treatment? Beyond safety, the study’s primary endpoint is percent weight loss for the combined treatment versus a placebo control at the end of treatment. A range of secondary endpoints, including satiety and preservation of lean body mass, were evaluated as well. Our obesity and weight loss management portfolio contains both a long-acting monoclonal 4 receptive selective peptide agonist and the orally active monoclonal 4 receptor selective small molecule PL 7737. Both programs remain on track to enter IND enabling activities in clinical studies during calendar 2025.

Carl Spana

executive
#7

Our new next-generation selective melanocortin-4 receptor compounds show less activity at the monoclonal 1 receptor, so they carry a lower potential for causing skin darkening. The absence of MCR 1 activity, together with once-weekly dosing or oral dosing, constitutes meaningful advances compared with the melanocortin treatments the FDA currently approves. More details about our clinical trial are available at clinicaltrials.gov, and recent presentations on our novel next-generation selective melanocortin-4 receptor compounds can be found on our website. As for OPL 8177, our selective monoclonal 1 receptor treatment, the Phase two study is still on schedule to report top line data during the first quarter of calendar 2025. Ahead of those data, business development discussions with potential partners have risen substantially, consistent with our present strategy of outlicensing this exciting program. In December of 2024, we released top line data from our Phase two breakout study of brimonidine as a treatment for patients with diabetic kidney disease. Among the study's key results, 71% of patients achieved a reduction of more than 30% in their urinary protein to creatinine ratio, and 71% of patients had an improved or stabilized estimated pulmonary filtration rate. These results confirm that the modulated line of cortin system could potentially serve as a new therapeutic strategy and possibly a disease-modifying treatment option for people living with progressive kidney disease.

Carl Spana

executive
#8

The full findings from the breakout study have been accepted for presentation at a medical conference. Given how well the study turned out, we've started talks with possible partners about out licensing this program, which aligns with the strategy we're pursuing right now. We said before that we're pursuing several avenues at once to capture the value of our ocular melanocortin program. Along those lines, we're actively in discussions with larger potential strategic partners regarding out licensing, with investors who want to fund further development, and with peer companies about possible business combinations. Before we move on to take questions, I'd like to say a few words about our strategy. Our research and development efforts are concentrated on the line of Cortisol four receptor BC assets. We think pharmacological treatment of obesity, during these early stages of a multiyear innovation cycle, will carry a market value above $100 billion per year. The Laticore system is essential for regulating stored energy and food intake. We firmly believe amyloidin four receptor agonists will play a significant role in the future of obesity treatment and weight loss management. Palatin Technologies, Inc. has carried out a long-standing research effort aimed at developing monoclonalcortin therapeutics that selectively activate the line of cortin four receptor as treatments for obesity and weight loss maintenance.

Carl Spana

executive
#9

Given how much work we’ve already done designing and developing Latticorn Agnes for obesity treatment—including 2 clinical studies that were completed and published earlier—we’re in a strong position to lead in developing Lidocort-based therapeutics aimed at weight loss and, crucially, keeping that weight off. Thanks for your time. We’ll now take questions.

Operator

operator
#10

Thanks. We'll now move into a question-and-answer session. The first question comes from Joe Pantginis at H.C. Wainwright. Joe, your line is open.

Joe Pantginis

analyst
#11

Hey, guys. Good morning. Good afternoon. I wanted to focus on the upcoming obesity data. I know you cannot say much right now after the database locks, but first, I wanted to just discuss the benchmark, and you can correct me if my numbers are wrong. So if you look at the tirzepatide data alone, after eight weeks, we are looking at about a 6% weight loss, maybe around 4% for placebo adjusted. So with that benchmark in mind, what would you consider a win for your study with regard to weight loss at eight weeks and whether it is the same or not, what would you consider to be enough percentage weight loss to move the program forward?

Carl Spana

executive
#12

Okay, that's a fair question, though we might frame it a bit differently. So, to answer you: this is a signal detection study. As a result, we aren't going in—either a priori or not a priori—with some specific frequency figure. Correct? What we're truly after is a very distinct signal. So, in this study, what we'd like to observe is a high percentage of weight loss in the combined arm. And beyond that, we're also examining certain other key metrics. For instance, the proportion of patients reaching 4, 5, 6, 7, or 8% weight loss during that eight-week period—combined versus tirzepatide alone. Since that matters somewhat more. It's a more important clinical question. Right? If you start someone on this, how many will achieve, say, 5% weight loss, which is genuinely clinically meaningful and at the FDA approval threshold. So that's one message we're considering. The second way to view it is that tirzepatide proceeds as if you're thinking in four-week increments.

Carl Spana

executive
#13

Correct? Tirzepatide used alone will likely reach its peak effect within the initial 4 weeks. It's going to begin tapering off. Yep. And then continue from that point onward. So is it possible to turn that deceleration around? Right? Can we observe a greater number of patients shedding more pounds, you know, during the second 4 weeks, let's say, compared with the first 4 weeks, when we compare the coadministration group against the monotherapy group? So those are all — those are the 3 things we're watching for. We're watching for a rise in absolute weight measured as a percentage. There's no figure, there's no magic figure. What I mean by saying that is this isn't an optimized study. You know, this is a very low dose of brimonidine. So, you know, we aren't optimized for, you know, necessarily seeing some large jump. But I think we certainly are, you know, dosing at a level high enough to capture a good clear signal. The other thing I do want to raise, though, is really when we discuss, you know, the combination group versus the monotherapy group. Let's consider the brimonidine-only group versus the placebo group. I'd expect, yep, you know, once placebo patients who are receiving placebo, you know, they will experience weight loss during their first treatment period on tirzepatide.

Carl Spana

executive
#14

They ought to put the weight back on. And we’re genuinely eager to find out whether this low dose is able to blunt that regain. That really gets at the idea of maintaining weight loss. So those are, more or less, the three main concepts where we’re hoping to see a signal.

Joe Pantginis

analyst
#15

No, I completely get how you're viewing it, and that logic holds up. I suppose what prompted my question is that from the analyst's perspective and the investment community's perspective, they're going to be, rightly or wrongly, automatically drawing that comparison against the benchmark. So that's what's driving what would be expected to be a win on a percentage basis, but I understand your approaches here and it makes sense. I guess looking ahead for the program, are there additional indications you might consider beyond the broader weight loss community? Any orphan indications you might consider from an MCR four standpoint?

Carl Spana

executive
#16

Absolutely, of course. Look, I believe there's a widening chance to consider Melanocortin four receptor agonists for rare and orphan syndromic diseases. Several mutations exist in the leptin and the right quadrant system. Prader Willi syndrome is one. Bardet Biedl is another. These aren't obscure matters. Rhythm is active in this area, after all. They have their products, and there's plenty of typo activity there. But hypothalamic obesity stands out as a really crucial one, since it's likely the biggest market opportunity. And it's one where we believe our new compounds in development will prove highly competitive. In a good way, that puts us alongside one other player in monoclonal four receptor agonists examining that orphan rare space — just the two of us. Once you move to the general obesity side, even though I think this mechanism is the best, we're going to be shifted toward a range of other mechanisms out there. So I think we will likely be concentrating on that rare space.

Joe Pantginis

analyst
#17

No, that’s reasonable — and best of luck with the data coming up. I really appreciate all the specifics.

Carl Spana

executive
#18

Absolutely.

Operator

operator
#19

Thanks. And with no further questions right now, I'd like to turn the call back over to Dr. Carl Spana for his closing remarks.

Carl Spana

executive
#20

Thanks, Joe. Thanks for the questions. And everyone, thanks for spending time with us. Steve and I are always grateful that you give us your time and take meetings with us to talk about the company. Hope you have a great day. We've got an exciting quarter ahead. We're really looking forward to it — 2025 is actually going to be exciting for us. So we really couldn't be more excited about what we're doing here, and we look forward to reporting our results. So from Steve and me, thank you everybody. Have a great day and a great quarter. Thank you.

Operator

operator
#21

Thanks. That brings today's conference to a close. At this point you're free to disconnect your lines. We appreciate you taking part.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.